Protocol Ledger

NCT06697301 · Phase II/III · RECRUITING

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

Interventional Phase II/III clinical trial protocol NCT06697301 sponsored by Eikon Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-05-22 Enrollment: 740 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06697301
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)740 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06697301
Protocol FieldVerified Registry Value
NCT IdentifierNCT06697301
Consolidated Lead SponsorEikon Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment740 participants (ESTIMATED)
Registered Start Date2025-05-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06697301
Hospital Research SiteLocationSite Profile
Providence Medical FoundationSanta Rosa, CAOpen Hospital Dossier ->
UCHealth Memorial Hospital CentralColorado Springs, COOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI